These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 39192083)

  • 1. Correlation between natural history and multi-omics profiling of meningiomas in NF2-related schwannomatosis suggests role of methylation group and immune microenvironment in tumor growth rate.
    Teranishi Y; Yurchenko A; Tran S; Sievers P; Rajabi F; Ruchith S; Abi-Jaoude S; Blouin A; Bielle F; Cazals-Hatem D; Sahm F; Nikolaev S; Kalamarides M; Peyre M
    Acta Neuropathol; 2024 Aug; 148(1):30. PubMed ID: 39192083
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
    Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
    Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role and regulatory mechanism of IL-1β on the methylation of the NF2 gene in benign meningiomas and leptomeninges.
    Wang B; Cui Z; Zhong Z; Sun Y; Yang GY; Sun Q; Bian L
    Mol Carcinog; 2016 Dec; 55(12):2268-2277. PubMed ID: 26840621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors.
    Smith MJ; Wallace AJ; Bowers NL; Eaton H; Evans DG
    Cancer Genet; 2014 Sep; 207(9):373-8. PubMed ID: 24933152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.
    Kehrer-Sawatzki H; Kluwe L; Friedrich RE; Summerer A; Schäfer E; Wahlländer U; Matthies C; Gugel I; Farschtschi S; Hagel C; Cooper DN; Mautner VF
    Hum Genet; 2018 Jul; 137(6-7):543-552. PubMed ID: 30006736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
    Lu-Emerson C; Plotkin SR
    Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schwannomatosis: a genetic and epidemiological study.
    Evans DG; Bowers NL; Tobi S; Hartley C; Wallace AJ; King AT; Lloyd SKW; Rutherford SA; Hammerbeck-Ward C; Pathmanaban ON; Freeman SR; Ealing J; Kellett M; Laitt R; Thomas O; Halliday D; Ferner R; Taylor A; Duff C; Harkness EF; Smith MJ
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1215-1219. PubMed ID: 29909380
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Forde C; Smith MJ; Burghel GJ; Bowers N; Roberts N; Lavin T; Halliday J; King AT; Rutherford S; Pathmanaban ON; Lloyd S; Freeman S; Halliday D; Parry A; Axon P; Buttimore J; Afridi S; Obholzer R; Laitt R; Thomas O; Stivaros SM; Vassallo G; Evans DG
    J Med Genet; 2024 Aug; 61(9):856-860. PubMed ID: 38925914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis.
    González-Rodriguez MA; Troutman S; Bayle S; Lester DK; Grove M; Duckett D; Kareta MS; Kissil JL
    Oncogene; 2024 Sep; 43(40):2995-3002. PubMed ID: 39209965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.
    Rutland JW; Gill CM; Loewenstern J; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Shrivastava RK; Fowkes M
    Cancer Immunol Immunother; 2021 Jan; 70(1):169-176. PubMed ID: 32661686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
    Chang LS; Oblinger JL; Smith AE; Ferrer M; Angus SP; Hawley E; Petrilli AM; Beauchamp RL; Riecken LB; Erdin S; Poi M; Huang J; Bessler WK; Zhang X; Guha R; Thomas C; Burns SS; Gilbert TSK; Jiang L; Li X; Lu Q; Yuan J; He Y; Dixon SAH; Masters A; Jones DR; Yates CW; Haggarty SJ; La Rosa S; Welling DB; Stemmer-Rachamimov AO; Plotkin SR; Gusella JF; Guinney J; Morrison H; Ramesh V; Fernandez-Valle C; Johnson GL; Blakeley JO; Clapp DW;
    PLoS One; 2021; 16(7):e0252048. PubMed ID: 34264955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders.
    Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Druker H; Scott HS; Tabori U
    Clin Cancer Res; 2017 Jun; 23(12):e54-e61. PubMed ID: 28620005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.
    Antinheimo J; Sankila R; Carpén O; Pukkala E; Sainio M; Jääskeläinen J
    Neurology; 2000 Jan; 54(1):71-6. PubMed ID: 10636128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
    Kalamarides M; Stemmer-Rachamimov AO; Takahashi M; Han ZY; Chareyre F; Niwa-Kawakita M; Black PM; Carroll RS; Giovannini M
    Brain Pathol; 2008 Jan; 18(1):62-70. PubMed ID: 17924978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues.
    Kim BH; Chung YH; Woo TG; Kang SM; Park S; Kim M; Park BJ
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.
    ; Allaway R; Angus SP; Beauchamp RL; Blakeley JO; Bott M; Burns SS; Carlstedt A; Chang LS; Chen X; Clapp DW; Desouza PA; Erdin S; Fernandez-Valle C; Guinney J; Gusella JF; Haggarty SJ; Johnson GL; La Rosa S; Morrison H; Petrilli AM; Plotkin SR; Pratap A; Ramesh V; Sciaky N; Stemmer-Rachamimov A; Stuhlmiller TJ; Talkowski ME; Welling DB; Yates CW; Zawistowski JS; Zhao WN
    PLoS One; 2018; 13(6):e0197350. PubMed ID: 29897904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours.
    Dave F; Herrera K; Lockley A; van de Weijer LL; Henderson S; Sofela AA; Hook L; Adams CL; Ercolano E; Hilton DA; Maze EA; Kurian KM; Ammoun S; Hanemann CO
    Oncogene; 2024 Oct; 43(41):3049-3061. PubMed ID: 39179860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
    Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG
    Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four distinct ipsilateral vestibular schwannomas: A case of mosaic NF2-related schwannomatosis.
    Tunkel AE; Youner ER; Barseghyan H; Fu Y; Bhattacharya S; Bornhorst M; Monfared AS
    Am J Clin Pathol; 2024 Aug; 162(2):110-114. PubMed ID: 38527168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.